A study of gene expression by RNA-seq in patients with prostate cancer and in patients with Parkinson disease: an example of inverse comorbidity.
Inverse comorbidity
NGS
Parkinson disease
Prostate cancer
Journal
Molecular biology reports
ISSN: 1573-4978
Titre abrégé: Mol Biol Rep
Pays: Netherlands
ID NLM: 0403234
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
23
08
2021
accepted:
27
09
2021
pubmed:
11
10
2021
medline:
22
2
2022
entrez:
10
10
2021
Statut:
ppublish
Résumé
Prostate cancer (PCa) is one of the leading causes of death in Western countries. Environmental and genetic factors play a pivotal role in PCa etiology. Timely identification of the genetic causes is useful for an early diagnosis. Parkinson's disease (PD) is the most frequent neurodegenerative movement disorder; it is associated with the presence of Lewy bodies and genetic factors are involved in its pathogenesis. Several studies have indicated that the expression of target genes in patients with PD is inversely related to cancer development; this phenomenon has been named "inverse comorbidity". The present study was undertaken to evaluate whether a genetic dysregulation occurs in opposite directions in patients with PD or PCa. In the present study, next-generation sequencing transcriptome analysis was used to assess whether a genetic dysregulation in opposite directions occurs in patients with PD or PCa. The genes SLC30A1, ADO, SRGAP2C, and TBC1D12 resulted up-regulated in patients with PD compared to healthy donors as controls and down-regulated in patients with PCa compared with the same control group. These results support the hypothesis of the presence of inverse comorbidity between PD and PCa.
Sections du résumé
BACKGROUND
BACKGROUND
Prostate cancer (PCa) is one of the leading causes of death in Western countries. Environmental and genetic factors play a pivotal role in PCa etiology. Timely identification of the genetic causes is useful for an early diagnosis. Parkinson's disease (PD) is the most frequent neurodegenerative movement disorder; it is associated with the presence of Lewy bodies and genetic factors are involved in its pathogenesis. Several studies have indicated that the expression of target genes in patients with PD is inversely related to cancer development; this phenomenon has been named "inverse comorbidity". The present study was undertaken to evaluate whether a genetic dysregulation occurs in opposite directions in patients with PD or PCa.
METHODS AND RESULTS
RESULTS
In the present study, next-generation sequencing transcriptome analysis was used to assess whether a genetic dysregulation in opposite directions occurs in patients with PD or PCa. The genes SLC30A1, ADO, SRGAP2C, and TBC1D12 resulted up-regulated in patients with PD compared to healthy donors as controls and down-regulated in patients with PCa compared with the same control group.
CONCLUSIONS
CONCLUSIONS
These results support the hypothesis of the presence of inverse comorbidity between PD and PCa.
Identifiants
pubmed: 34628580
doi: 10.1007/s11033-021-06723-0
pii: 10.1007/s11033-021-06723-0
doi:
Substances chimiques
Neoplasm Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7627-7631Subventions
Organisme : The Italian "5 x 1000" funding
ID : This study was supported by The Italian "5 x 1000" funding
Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49(6):1374–1403
doi: 10.1016/j.ejca.2012.12.027
Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63(1):11–30
doi: 10.3322/caac.21166
Kingsley LA, Fournier PG, Chirgwin JM, Guise TA (2007) Molecular biology of bone metastasis. Mol Cancer Ther 6(10):2609–2617
doi: 10.1158/1535-7163.MCT-07-0234
Tantivejkul K, Kalikin LM, Pienta KJ (2004) Dynamic process of prostate cancer metastasis to bone. J Cell Biochem 91(4):706–717
doi: 10.1002/jcb.10664
Hadaschik BA, Gleave ME (2007) Therapeutic options for hormone-refractory prostate cancer in. Urol Oncol 25(5):413–419
doi: 10.1016/j.urolonc.2007.05.010
Zhang H, Qi C, Wang A, Yao B, Li L, Wang Y et al (2013) Prognostication of prostate cancer based on NUCB2 protein assessment: NUCB2 in prostate cancer. J Exp Clin Cancer Res 32:77
doi: 10.1186/1756-9966-32-77
Lang AE, Lozano AM (1998) Parkinson’s disease first part. N Engl J Med 339:1044–1053
doi: 10.1056/NEJM199810083391506
Lang AE, Lozano AM (1998) Parkinson’s disease second part. N Engl J Med 339:1130–1143
doi: 10.1056/NEJM199810153391607
Jellinger KA (2012) Neuropathology of sporadic Parkinson’s disease: evaluation and changes of concepts. Mov Disord 27:8–30
doi: 10.1002/mds.23795
Tabare´s-Seisdedos R, Dumont N, Baudot A, Valderas JM, Climent J et al (2011) No paradox, no progress: inverse cancer comorbidity in people with other complex diseases. Lancet Oncol 12:604–608
doi: 10.1016/S1470-2045(11)70041-9
Tabare´s-Seisdedos R, Rubensteinm JL (2013) Inverse cancer comorbidity: a serendipitous opportunity to gain insight into CNS disorders. Nat Rev Neurosci 14:293–304
doi: 10.1038/nrn3464
Devine MJ, Plun-Favreau H, Wood NW (2011) Parkinson’s disease and cancer: two wars, one front. Nat Rev Cancer 11:812–823
doi: 10.1038/nrc3150
West AB, Dawson VL, Dawson TM (2005) To die or grow: Parkinson’s disease and cancer. Trends Neurosci 28:348–352
doi: 10.1016/j.tins.2005.05.002
Liu QX, Zheng H, Deng XF, Zhou D, Dai JG (2015) Status of the Parkinson’s disease gene family expression in non-small-cell lung cancer. World J Surg Oncol 13
Liu L, Zuo Z, Lu S, Wang L, Liu A, Liu X (2018) Silencing of PINK1 represses cell growth, migration and induces apoptosis of lung cancer cells. Biomed Pharmacother 106:333
doi: 10.1016/j.biopha.2018.06.128
Jin Y, Murata H, Sakaguchi M et al (2012) Partial sensitization of human bladder cancer cells to a gene-therapeutic adenovirus carrying REIC/Dkk-3 by downregulation of BRPK/PINK1. Oncol Rep 27:695
pubmed: 22076283
Wong KHK, Tessier SN, Miyamoto DT, Miller KL, Bookstaver LD, Carey TR, Stannard CJ, Thapar V, Tai EC, Vo KD et al (2017) Whole blood stabilization for the microfluidic isolation and molecular characterization of circulating tumor cells. Nat Commun 23:1733
doi: 10.1038/s41467-017-01705-y
Postuma RB, Berg D, Stern M et al (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 30:159–1601
Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL (2005) ISUP Grading Committee. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 1:228–242
Salemi M, Marchese G, Cordella A, Cannarella R, Barone C, Salluzzo MG, Calogero AE, Romano C (2020) Long non-coding RNA GAS5 expression in patients with Down syndrome. Int J Med Sci 23:1315–1319
doi: 10.7150/ijms.45386
Love MI, Huber W, Anders S (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15:550
doi: 10.1186/s13059-014-0550-8
Anders S, Pyl PT, Huber W (2015) HTSeq--a Python framework to work with high-throughput sequencing data. Bioinformatics 31:166–169
doi: 10.1093/bioinformatics/btu638
Pomaznoy M, Ha B, Peters B (2018) GO net: a tool for interactive Gene Ontology analysis. BMC Bioinformatics 7:470
doi: 10.1186/s12859-018-2533-3
Palmiter RD, Findley SD (1995) Cloning and functional characterization of a mammalian zinc transporter that confers resistance to zinc. EMBO J 14:639–649
doi: 10.1002/j.1460-2075.1995.tb07042.x
Singh CK, Malas KM, Tydrick C, Siddiqui IA, Iczkowski KA, Ahmad N (2016) Analysis of zinc-exporters expression in prostate. Cancer Sci Rep 11:36772
Adlard PA, Parncutt JM, Finkelstein DI, Bush AI (2010) Cognitive loss in zinc transporter-3 knock-out mice: a phenocopy for the synaptic and memory deficits of Alzheimer’s disease? J Neurosci 30:1631–1636
doi: 10.1523/JNEUROSCI.5255-09.2010
Dominy JE, Simmons CR, Hirschberger LL, Hwang J, Coloso RM, Stipanuk MH (2007) lkDiscovery and characterization of a second mammalian thiol dioxygenase, cysteamine dioxygenase. J Biol Chem 282:25189
doi: 10.1074/jbc.M703089200
Sarkar B, Kulharia M, Mantha AK (2017) Understanding human thiol dioxygenase enzymes: structure to function, and biology to pathology. Int J Exp Pathol (2017) 98: 52–66
Guerrier S, Coutinho-Budd J, Sassa T, Gresset A, Jordan NV, Chen K, Jin WL, Frost A, Polleux F (2009) The F-BAR domain of srGAP2 induces membrane protrusions required for neuronal migration and morphogenesis. Cell 138:990–1004
doi: 10.1016/j.cell.2009.06.047
Guo S, Bao S (2010) srGAP2 arginine methylation regulates cell migration and cell spreading through promoting dimerization. J Biol Chem 285:35133–35141
doi: 10.1074/jbc.M110.153429
Oguchi ME, Noguchi K, Fukuda M (2017) TBC1D12 is a novel Rab11-binding protein that modulates neurite outgrowth of PC12 cells. PLoS One 6(4):12 e0174883.
Catalá-López F, Suárez-Pinilla M, Suárez-Pinilla P, Valderas JM, Gómez- Beneyto M, Martinez S, Balanzá-Martínez V, Climent J, Valencia A, McGrath J et al (2014) Inverse and direct cancer comorbidity in people with central nervous system disorders: a meta-analysis of cancer incidence in 577,013 participants of 50 observational studies. Psychother Psychosom 83(2):89–105
doi: 10.1159/000356498
Forés-Martos J, Boullosa C, Rodrigo-Domínguez D, Sánchez-Valle J, Suay-García B, Climent J, Falcó A, Valencia A, Puig-Butillé JA, Puig S, Tabarés-Seisdedos R (2021) Transcriptomic and genetic associations between Alzheimer’s disease, Parkinson’s disease, and cancer. Cancers (Basel) 13(12):2990. https://doi.org/10.3390/cancers13122990
doi: 10.3390/cancers13122990
Mogavero MP, Silvani A, DelRosso LM, Salemi M, Ferri R (2021) Focus on the complex interconnection between cancer, narcolepsy and other neurodegenerative diseases: a possible case of orexin-dependent inverse comorbidity. Cancers (Basel) 13(11):2612. https://doi.org/10.3390/cancers13112612
doi: 10.3390/cancers13112612